FDA Hatch/Waxman “Moot Court” To Examine Brand/Generic Legal Positions
This article was originally published in The Tan Sheet
Executive Summary
FDA's chief counsel will host a "moot court" briefing on the brand and generic industry's arguments about the agency's interpretation of the Hatch/Waxman Act